Dr. Petr F. Hausner
While treating patients is Dr. Hausner’s main focus, he is also involved in research, an important part of working at a teaching university. With more than 100 clinical trials ongoing at the Greenebaum Cancer Center, Dr. Hausner has the opportunity to pursue new modes of inquiry about cancer in pursuit of a cure. This can also be a benefit to patients at Greenebaum, who have access not only to standard methods of treatment like chemotherapy and surgery, but also to experimental drugs and brand new treatment options.
Because the University of Maryland is among the top 25 rated cancer centers in the United States, Dr. Hausner’s office is often a beacon of hope for patients who have been unsuccessful in their treatments elsewhere. An experienced staff allows Dr. Hausner’s office to treat these patients successfully.
In his laboratory, Dr. Hausner studies intercellular communications and the process by which mesothelioma cells spread — a hugely important task if researchers hope to understand and eventually eradicate the disease. And in addition to his work at the University of Maryland, Dr. Hausner also serves as Chief of Hemotology and Oncology at the Baltimore VA Medical Center.
Main Specialty: Oncology
Other Interests & Specialties: General oncology, internal medicine, metastasis, skin cancer, chemotherapy, melanoma, kaposi sarcoma, gastrointestinal cancer, cancer biology, mesothelioma, DNA repair and hematologic oncology.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Internal Medicine, CMS Stage 1 EHR Certification
Education & Experience:
- Fellowship in Medical Oncology at National Institutes of Health Clinical Center
- Residency at Charles University
- Medical Degree from Charles University
Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. Molecular and Cellular Pharmacology. Jan 2013;5(1):19-25. doi: 10.4255/mcpharmacol.13.04
18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clinical Nuclear Medicine. May 2012;37(5):492-494. doi: 10.1097/RLU.0b013e3182478bb5
Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Annals of Thoracic Surgery. January 2010; 89(1): 200-206; doi: 10.1016/j.athoracsur.2009.08.069
Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Annals of Thoracic Surgery. September 2018; 86(3):903-10. doi: 10.1016/j.athoracsur.2008.06.022
Current Treatment Options and Biology of Peritoneal Mesothelioma: Meeting Summary of the First NIH Peritoneal Mesothelioma Conference. Annals of Oncology. November 2006;17(11):1615-1619. doi: 10.1093/annonc/mdl060"
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell-lung cancer. Journal of Clinical Oncology. August 2005;23(24):5774-57788. doi: 10.1200/JCO.2005.14.373
High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. Journal of Thoracic and Cardiovascular Surgery. June 2005;129(6):1250-1257. doi: 10.1016/j.jtcvs.2004.12.050